Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 81Carcinoma, Hepatocellular 4Neoplasms 3Carcinoma, Renal Cell 3Prostatic Diseases 2Prostate Adenocarcinoma 2Ovarian Neoplasms 2Carcinoma, Adenoid Cystic 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stage II Prostate Adenocarcinoma 1Renal Insufficiency 1Prostatic Neoplasms, Castration-Resistant 1Prostate-specific Membrane Antigen 1Prostate Cancer Metastatic 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasm Metastasis 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Melanoma 1Lung Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Lobular 1

Interventions

Dexamethasone 13Bortezomib 8Cyclophosphamide 6Lenalidomide 5pomalidomide 3isatuximab 3glucarpidase 3Kidney Transplantation 3Calcium Dobesilate 3Thalidomide 2Paclitaxel 2Gemcitabine 2Carboplatin 2Blood Specimen Collection 2Bendamustine Hydrochloride 2Azacitidine 2vinflunine 1veliparib 1trifluridine tipiracil drug combination 1trebananib 1safinamide 1sacubitril and valsartan sodium hydrate drug combination 1rubitecan 1ripretinib 1regorafenib 1pevonedistat 1pembrolizumab 1osimertinib 1mirabegron 1melflufen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Insufficiency × gallium 68 PSMA-11 × Clear all
NCT06004661 2026-03-06

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Novartis

Phase 2 Recruiting
20 enrolled

Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡